Amarin | AMRN - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 43.1B 1.46B 2026-09
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amarin USD 175.14M 10.94M 2026-09
AstraZeneca USD 31.27B 286M 2026-09
BioCryst Pharmaceuticals USD 195.83M 13.02M 2026-09
DBV Technologies USD 58.5M 4.2M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Halozyme Therapeutics USD 476.09M 131.65M 2026-09
Heron Therapeutics USD 92.14M 1.63M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Novartis USD 32.52B 777M 2026-09